In men with PSA relapse following prostatectomy, androgen deprivation is commonly used to slow tumor progression.
However, reducing androgen (namely testosterone) levels can seriously impact quality of life for patients undergoing this treatment.
Researchers from Germany presented data comparing the use of continuous androgen deprivation (CAD) therapy to intermittent androgen deprivation (IAD) therapy in these patients to compare both efficacy and patient tolerability between these two forms of hormonal treatment.
No statistically significant difference was seen in androgen-independent disease progression between the two groups. However, patients treated with IAD had an improved quality of life and fewer hot flashes than the CAD group indicating that IAD may be a more attractive treatment option for patients with PSA relapse after primary treatment.